Mutated HEV polypeptides and the use thereof for assaying anti-HEV antibodies
US10408841B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 29, 2016 |
| Grant date | Sep 10, 2019 |
| Priority date | — |
| Expiry date | Nov 29, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/28122
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Polypeptides of the p-ORF2 protein of the hepatitis E virus, including at least the amino acid sequence 394-660, numbered in relation to a p-ORF2 protein of 660 amino acids, in which the three cysteines at positions 627, 630 and 638 have been mutated or, for a p-ORF2 protein of different length, at least the amino acid sequence corresponding to amino acids 394-660 of the p-ORF2 protein of 660 amino acids, in which the three cysteines located at the three positions corresponding to positions 627, 630 and 638 of the p-ORF2 protein of 660 amino acids have been mutated. Also, methods for determining the presence of the humoral response or the titer of antibodies directed against the p-ORF2 protein using these polypeptides, and also the use thereof in the context of infection with the hepatitis E virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.